ETNB · 89bio Inc

-

Please sign in to comment on ETNB

1 Comment

Admin

4 years, 1 month ago

89bio, Inc is currently in a long term downtrend where the price is trading 31.8% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

89bio, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 34.8% to $-13M since the same quarter in the previous year.

Finally, its free cash flow fell by 24.8% to $-14M since the same quarter in the previous year.

Based on the above factors, 89bio, Inc gets an overall score of 2/5.

Sector	Healthcare
Industry	Biotechnology
Exchange	NASDAQ
CurrencyCode	USD
ISIN	US2825591033

Beta	1.47
Market Cap	1B
PE Ratio	None
Target Price	29.5455
Dividend Yield	None

ABOUT

89bio Inc

89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.

ETNB · 89bio Inc

-

89bio Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest 89bio Inc using a moving average strategy